 FDA clearance for smoking cessation moves Brainsway towards a portfolio of neurological disorder treatments and extends the companys competitive advantage. The publication of positive real-world results for treating OCD adds support to the case for insurance reimbursement, although cost effectiveness is still a potential barrier. 